摘要
本研究通过给予动脉粥样硬化Apo E^-/-小鼠不同剂量的缬沙坦（1 mg/kg,10 mg/kg）,连续灌胃2周,观察其治疗效果,并分析正常饲养小鼠、动脉粥样硬化模型小鼠以及不同缬沙坦剂量组治疗小鼠干扰素系统蛋白和炎症反应蛋白水平的变化。研究表明,小鼠动脉粥样硬化管腔面积明显降低,斑块面积、血管内膜厚度及脂质中心面积明显升高,血清中干扰素（IFNα,IFNβ,IFNγ）、干扰素调节蛋白（IRF1,IRF2,IRF4,IRF8）、炎症反应因子（IL2,IL4,IL6,IL10,IL15）、质金属蛋白酶（MMP1,MMP9,TIMP1和TIMP3）等的表达水平均显著升高（p〈0.01）,且与正常饲养小鼠、动脉粥样硬化模型小鼠相比有显著的统计学差异（p〈0.01）,缬沙坦治疗后缬沙坦10 mg/kg组明显优于缬沙坦1 mg/kg组（p〈0.01）。因此,缬沙坦可能通过调控干扰素系统蛋白及炎症反应蛋白水平来改善小鼠动脉粥样硬化。此结果为探讨缬沙坦在改善动脉粥样硬化小鼠中的作用机制进一步深入研究提供理论依据,为临床治疗和新药开发提供参考方向。
This study given different doses of Stan（1 mg/kg,10 mg/kg） for Apo E^-/-mice with atherosclerosis,continuous intragastric administration for 2 weeks,observe the treatment effect of Stan,and analysis the change of normal group,atherosclerosismodel group and treated group with different doses of Stan with interferon system protein and protein level of inflammation.Studies show that atherosclerosis mice significantly reduced lumen area,plaque area,intimal thickness and lipid center area increased significantly,serum interferon（IFN,interferon alpha,IFN beta,IFN gamma）,interferon regulatory proteins（IRF1,IRF2,IRF4,IRF8）,inflammatory factor（IL2,IL4,IL6,IL10,IL15）,matrix metalloproteinase（MMP1,MMP9,TIMP1 and TIMP3） expression levels were significantly increased（p〈0.01）,compared with normal mice fed mice,atherosclerosis model was statistically significant（p〈0.01）,valsartan treatment after valsartan group for 10 mg/kg was significantly better than valsartan group for 1 mg/kg（p〈0.01）.Thus,valsartan may improve atherosclerosis in mice by modulating the levels of interferon system proteins and inflammatory response proteins.The results provide theoretical basis for further study on the mechanism of valsartan in atherosclerosis mice,and provide a reference direction for clinical treatment and new drug development.
作者
朱晓刚
王丽岳
王丽江
任浩进
刘金华
Zhu Xiaogang;Wang Liyue;Wang Lijiang;Ren Haojin;Liu Jinhua(Wuhan Puren Hospital, Wuhan, 430081;Third Hospital of Wuhan City, Wuhan, 430060)
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2018年第5期2312-2319,共8页
Genomics and Applied Biology
基金
国家自然基金项目(No.81402915)资助
